Skip to content

Efficacy of High-Dose versus Intermediate-Dose Intravenous Dexamethasone in Reducing Pain Following Bilateral Total Knee Arthroplasty

Efficacy of High-Dose versus Intermediate-Dose Intravenous Dexamethasone in Reducing Pain Following Bilateral Total Knee Arthroplasty

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250104002
Enrollment
40
Registered
2025-01-04
Start date
2025-01-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral total knee arthroplasty in primary osteoarthritis of both knees Bilateral total knee arthroplasty , Dexamethasone, Post-operative pain control, Primary osteoarthritis of knee

Interventions

Dexamethasone 8 mg at intra-operation and 24 hours post-operation,Dexamethasone 16 mg at intra-operation and 24 hours post-operation
Active Comparator Drug,Experimental Drug
Intermediate dose dexamethasone,High dose dexamethasone

Sponsors

Buddhachinaraj Phitsanulok Hospital, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patient undergoing bilateral TKA due to osteoarthritis of both knees 2.Age between 55-85 year olds 3.Weight between 50-90 kilograms 4.Abel to undergo spinal anesthesia for pain control during surgery 5.Assessed as ASA classification level 1-2 6.Willing to participate in research study with signed consent 7.Able to communicate read and write in Thai

Exclusion criteria

Exclusion criteria: 1.Use of corticosteroids within the past 3 months 2.Used of immunosuppressant drugs with in the past 3 months 3.Use of strong opioids within the past 7 days 4.Diagnosed with Diabetes mellitus 5.Suspected or diagnosed infectious disease 6.History of allergies to dexamethasone, opioids, tranexamic acid, paracetamol, omeprazole or lorazepam 7.History of gastric ulcer, severe heart disease, liver failure or renal failure 8.Unable to cooperate effectively 9.Participant decline or request to withdraw from this study

Design outcomes

Primary

MeasureTime frame
Pain Post operative at 8h, 16h, 24h, 48h, 72h Visual analog scale

Secondary

MeasureTime frame
Range of motion knee Post operative at 24h , 48h, 72h Degree,Knee circumference Post operative at 24h , 48h, 72h Centimeter,Blood glucose Post operative at 24h , 48h, 72h Blood glucose level,Time up and go Post operative at 72h Second,Morphine consumption Post operative at 24h , 48h, 72h Miligram

Countries

Thailand

Contacts

Public ContactKatawut Kumplean

Buddhachinaraj Phitsanulok Hospital, Thailand

katawut.ktw@gmail.com0870535533

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026